FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item)
(‎Created claim: summary (P836): GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH, Adding English summary)
Property / summary
 
GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
Property / summary: GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English) / rank
 
Normal rank

Revision as of 09:46, 23 March 2020

Project in Italy financed by DG Regio
Language Label Description Also known as
English
FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES
Project in Italy financed by DG Regio

    Statements

    0 references
    186,460.21 Euro
    0 references
    372,920.43 Euro
    0 references
    50.0 percent
    0 references
    14 February 2017
    0 references
    13 October 2019
    0 references
    EVVIVAX S.R.L.
    0 references
    ISTITUTO SUPERIORE DI SANITA'
    0 references
    0 references
    0 references

    41°53'35.95"N, 12°28'58.55"E
    0 references
    I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà, LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
    0 references
    GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
    0 references

    Identifiers

    F89J18000160007
    0 references